Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Exploratory, Proof-of-Concept, Early-Stage, Randomized, Double-Blind, Vehicle and Active Controlled, Intra-Individual, Phase I/II Study to Evaluate the Safety and Efficacy of SNA-125 Gel for Treatment of Atopic Dermatitis

Trial Profile

An Exploratory, Proof-of-Concept, Early-Stage, Randomized, Double-Blind, Vehicle and Active Controlled, Intra-Individual, Phase I/II Study to Evaluate the Safety and Efficacy of SNA-125 Gel for Treatment of Atopic Dermatitis

Completed
Phase of Trial: Phase I/II

Latest Information Update: 03 Dec 2018

At a glance

  • Drugs SNA 125 (Primary)
  • Indications Atopic dermatitis
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Sponsors Sienna Biopharmaceuticals
  • Most Recent Events

    • 03 Dec 2018 Status changed from active, no longer recruiting to completed.
    • 03 Dec 2018 Results presented in a Sienna Biopharmaceuticals media release.
    • 27 Aug 2018 Status changed from recruiting to active, no longer recruiting, according to a Sienna Biopharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top